Home / Pharmaceuticals / Anti-epileptic Drugs Market By Drug Class (Hydantoin derivatives, Iminostilbenes, Long acting barbiturates, Succinimides, Benzodiazepines, Carbonic anhydrase inhibitors (CAI), GAMA- vinyl – GABA, Amino acid derivatives, Monosaccharide derivatives, Others : Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives, Sulphonamide derivatives) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Anti-epileptic Drugs Market By Drug Class (Hydantoin derivatives, Iminostilbenes, Long acting barbiturates, Succinimides, Benzodiazepines, Carbonic anhydrase inhibitors (CAI), GAMA- vinyl – GABA, Amino acid derivatives, Monosaccharide derivatives, Others : Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives, Sulphonamide derivatives) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Published: Dec 2017 | Report Code: 58885-12-17

Epilepsy is a neurological disorder in which patient experiences epileptic seizures. These epileptic seizures are a result of the disturbance in the electrical communication in neurons. Seizures can vary from short period to long episodes of vigorous shaking. Epilepsy can be diagnosed in a patient only after one or more seizure episodes. Patients may have more than one type of seizure and these seizures usually follow the same pattern each time they occur to the patient. Causes of epilepsy include patient’s genetics, tumor or brain injuries. Epileptic seizures are of two types, i.e. focal and generalized depending on the affected area of the brain. Symptoms which occur before seizures include nausea, headache, strange feeling and visual loss. Anti-epileptic drugs are used to treat this neurological disorder.

This market analysis report on anti-epileptic drugs market provides a detailed analysis of the market. This report explains key market trends and aids industry leaders in their strategic initiative and decision making. The report provides market value and forecast for the anti-epileptic drugs market.

The scope of the report comprises demarcation of the market in terms of drug class and geographical distribution. The drug class segments are further categorized into hydantoin derivatives, iminostilbenes, long-acting barbiturates, succinimides, benzodiazepines, carbonic anhydrase inhibitors (CAI), GAMA- vinyl – GABA, amino acid derivatives, monosaccharide derivatives, and others. Others include valproic acid derivatives, deoxy barbiturate, phenyltriazine, nicotinic acid derivatives and sulphonamide derivatives. Each segment is analyzed considering market drivers and restraints for the market value of anti-epileptic drugs market. CAGRs are provided for the forecast year 2017-2025 for each segment.

Based on geographical demarcation, the report provides analysis of following geographical segments along with major countries:

  • North America
    • Canada
    • United States
  • Europe
    • Germany
    • United Kingdom
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market estimation is also elucidated for above-mentioned segments in anti-epileptic drugs market. This regional market estimation is proved granularly by segmenting the regions by drug class and countries. CAGRs are calculated for the forecast year 2017-2025.

This report provides key insights about the global anti-epileptic drugs market including market drivers & restraints, key trends, opportunities, and regional outlook. Analysis tools such as Porter’s five forces along with competitive landscape analysis are also incorporated in this report. Leading players in the global anti-epileptic market are also profiled in this report. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Anti-epileptic Drugs Market Portraiture
2.1.1. Global Anti-epileptic Drugs Market, by Drug Class, 2016 (US$ Mn)
2.1.2. Global Anti-epileptic Drugs Market, by Geography, 2016 (US$ Mn)

Chapter 3. Anti-epileptic Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Epilepsy: Epidemiology
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2016
3.7. Value Chain Analysis
3.8. Major Agreements, Partnerships and Collaborations
3.9. Competitive Landscape
3.9.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Anti-epileptic Drugs Market, by Drug Class, 2015-2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition, by Drug Class, 2016
4.2. Hydantoin derivatives
4.2.1. Phenytoin
4.2.2. Fosphenytoin
4.3. Iminostilbenes
4.3.1. Carbamazepine
4.3.2. Oxcarbazepine
4.4. Long acting barbiturates
4.4.1. Phenobarbitone
4.4.2. Methobarbitone
4.5. Succinimides
4.5.1. Ethosuximide
4.5.2. Methsuximide
4.5.3. Phensuximide
4.6. Benzodiazepines
4.6.1. Clonazepam
4.6.2. Nitrazepam
4.6.3. Diazepam
4.7. Carbonic anhydrase inhibitors (CAI)
4.7.1. Acetazolamide
4.7.2. Sulthiame
4.8. GAMA- vinyl – GABA
4.8.1. Vigabatrin
4.9. Amino acid derivatives
4.9.1. GABA pentin
4.10. Monosaccharide derivatives
4.10.1. Topiramate
4.11. Others (Valproic acid derivatives, Deoxy barbiturate, Phenyltriazine, Nicotinic acid derivatives and Sulphonamide derivatives)
4.12. Phase III (Market estimations by 2025)
4.12.1. Brivaracetam or ucb 34714 (UCB Pharma)
4.12.2. Topiramate (Janssen Research & Development, LLC)
4.12.3. Levetiracetam (Janssen Research & Development, LLC)
4.12.4. Others
4.13. Tabular Presentation of Phase II (Qualitative Information)
4.14. Tabular Presentation of Phase Phase I (Qualitative Information)

Chapter 5. Global Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.2.1. North America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.2.2. North America Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.3.1. Europe Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.3.2. Europe Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.4.1. Asia Pacific Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.5.1. Latin America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Anti-epileptic Drugs Market Analysis, 2015 – 2025 (US$ Mn)
5.6.1. MEA Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.6.2. MEA Anti-epileptic Drugs Market, by Country, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Abide Therapeutics
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Application Portfolio
6.1.4. Key Developments
6.2. Advicenne Pharma SA
6.3. Alexza Pharmaceuticals
6.4. Argentum Pharmaceuticals
6.5. GlaxoSmithKline (GSK) plc
6.6. GW Pharmaceuticals Plc
6.7. Janssen Pharmaceuticals
6.8. Marinus Pharmaceuticals
6.9. Novartis Pharmaceuticals Corp
6.10. Otsuka Pharmaceuticals
6.11. Pfizer Inc.
6.12. Takeda Pharmaceutical Company Ltd
6.13. UCB Pharma

List of Tables

TABLE 1 Global Anti-epileptic Drugs Market Portraiture
TABLE 2 Global Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 3 Global Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 North America Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Anti-epileptic Drugs Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Anti-epileptic Drugs Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 14 Abide Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Advicenne Pharma SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Alexza Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Argentum Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 GlaxoSmithKline (GSK) plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 GW Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Janssen Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Marinus Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Novartis Pharmaceuticals Corp: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Otsuka Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Takeda Pharmaceutical Company Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 UCB Pharma: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

List of Figures

FIG. 1 Anti-epileptic Drugs: Market Segmentation
FIG. 2 Global Anti-epileptic Drugs Market, by Drug Class, 2016 (US$ Mn)
FIG. 3 Global Anti-epileptic Drugs Market, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2016
FIG. 5 Value Chain Analysis: Global Anti-epileptic Drugs Market
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Hydantoin derivatives (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Iminostilbenes (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Long acting barbiturates (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Succinimides (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Benzodiazepines (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Carbonic anhydrase inhibitors (CAI) (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global GAMA- vinyl – GABA (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Amino acid derivatives (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 15 Global Monosacharide derivatives (Anti-epileptic Drugs) Market, 2015 – 2025 (US$ Mn)
FIG. 16 Global Others Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 17 U.S. Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 18 Canada Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 19 U.K. Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 20 Germany Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 21 Rest of Europe Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 22 China Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 23 Japan Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Asia Pacific Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 25 Brazil Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 26 Mexico Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 27 Rest of Latin America Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 28 GCC Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)
FIG. 29 Rest of Middle East and Africa Anti-epileptic Drugs Market, 2015 – 2025 (US$ Mn)

A complete description is also presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which hold prominent position in the anti-epileptic drugs market globally. The major players in the global anti-epileptic drugs market are Abide Therapeutics, Advicenne Pharma SA, Alexza Pharmaceuticals, Argentum Pharmaceuticals, GlaxoSmithKline (GSK) plc, GW Pharmaceuticals, Janssen Pharmaceuticals, Marinus Pharmaceuticals, Novartis Pharmaceuticals Corp, Otsuka Pharmaceuticals, Pfizer, Inc., Takeda Pharmaceutical Company Ltd and UCB Pharma.

Based on the Drug Class, global anti-epileptic drugs market is segmented as follows:

  • Hydantoin derivatives
  • Iminostilbenes
  • Long acting barbiturates
  • Succinimides
  • Benzodiazepines
  • Carbonic anhydrase inhibitors (CAI)
  • GAMA- vinyl – GABA
  • Amino acid derivatives
  • Monosaccharide derivatives
  • Others
    • Valproic acid derivatives
    • Deoxy barbiturate
    • Phenyltriazine
    • Nicotinic acid derivatives
    • Sulphonamide derivatives

Anti-epileptic Drugs Market

Anti-epileptic drugs are classified based on the drug class. Each drug class has different mechanism of action for the treatment of epilepsy. Due to difference in mechanism of action, prescription of the drug depends on the type of seizures occurring to the patients. Most of the drugs are used as monotherapy and for partial onset seizures. Succinimides, hydantoin derivatives and benzodiazepines are mostly preferred by the doctorsVimpat, Fycompa, Lacosamide and Retigabine are some of the ant-epileptic drugs preferred by the physicians.

Increasing awareness about treatment with anti-epileptic drugs, patent expiration and approval of pipeline products are the factors responsible for the market growth. The global anti-epileptic drugs market is emerging at considerable pace because of high prevalence of epilepsy and more research and development activities involved.

Geographically, the global anti-epileptic drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.

 

Anti-epileptic Drugs Market

According to the estimation for the year 2016, North America dominated the global anti-epileptic drugs market by accounting major market share. In terms of market share, North America is followed by Europe. Increased healthcare expenditure, government initiatives and approval of new drugs are the prime factors regulating the market in these regions. For instance, a few years back, Eisai Co. Ltd. has launched Fycompa in Americas and Europe. Other factors for the market growth in this region include high prevalence of epilepsy and presence of treatment options in the region. According to the research, there are around 2.5 million cases of epilepsy in the U.S. and around 15,000 new cases of epilepsy are diagnosed each year in Canada. In terms of market value, Europe is followed by Asia Pacific. Due to the high prevalence of epilepsy in China and India and increased awareness of epilepsy are some of the major factors responsible for anti-epileptic drugs market growth.

The detailed geographical classification of the global anti-epileptic drugs market is as follows:

  • North America (U.S. & Canada)
  • Asia Pacific (Japan, China, and Rest of Asia Pacific)
  • Europe (Germany, U.K. and Rest of Europe)
  • Latin America (Mexico, Brazil, and Rest of Latin America)
  • Middle East and Africa (GCC and Rest of Middle East and Africa)
Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients